<正>Objective:Entecavir and tenofovir may have comparable efficacy in achieving surrogate endpoints,and are recommended as first-line treatments for patients with chronic hepatitis B(CHB).However,data regarding whether they have equivalent impacts on the risk of hepatocellular carcinoma(HCC)and mortality in CHB patients are sparse.
展开▼